If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-13. Numbers and descriptions here follow the published literature rather than marketing material.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
=== Functional Genomics === This program studies genes involved in physiological systems and their pharmaceutical applications. It characterizes gene functions and interactions using rodent models at the Czech Centre for Phenogenomics, which is part of the Infrafrontier consortium. Research includes liver function, cardiovascular dysfunction, diabetes, metabolic disorders, hearing loss, and ocular disease.
The serum total clearance of CPA is approximately 2.32 ± 0.38 mL/min/kg. Levels of CPA and 15β-OH-CPA with oral administration decrease biphasically over a period of 24 to 120 hours. The elimination of CPA appears to be biphasic. In one study, a peak at 3.4 hours post-dose with an initial half-life of 3.4 hours and later half-life of 1.6 days was observed following a single 50 mg oral dose of CPA. The high lipophilicity and fat storage of CPA may be the reason for its longer subsequent half-life.
=== Books === Wadden, Thomas A.; Van Itallie, Theodore B. (1992). Treatment of the Seriously Obese Patient. Guilford Press. Stunkard, Albert J.; Wadden, Thomas A. (1993). Obesity: Theory and Therapy (2nd ed.). Raven Press. Brownell, Kelly D.; Wadden, Thomas A. (1998). The LEARN Program for Weight Control: Special Medication Edition. American Health Publishing. Wadden, Thomas A.; Stunkard, Albert J. (2002). Handbook of Obesity Treatment. Guilford Press. Wadden, Thomas A.; Bray, George A. (2018). Handbook of Obesity Treatment (2nd ed.). Guilford Press.
== F == Facial nerve (Cranial Nerve VII) A cranial nerve that controls the muscles of facial expression, conveys taste sensations from the anterior two-thirds of the tongue, and carries parasympathetic fibers to salivary and lacrimal glands. Facilitation A short-term increase in synaptic strength resulting from prior activity, due to residual calcium in the presynaptic terminal. It contributes to short-term plasticity and temporal coding. Fear conditioning A form of associative learning in which a neutral stimulus becomes associated with an aversive event. It is often used to study emotional memory and the role of the amygdala. Fiber tract A bundle of axons in the central nervous system that connects different brain regions. Examples include the corpus callosum, optic tract, and corticospinal tract. Field potential An electrical potential recorded from a population of neurons, often reflecting the summed synaptic input to a region. Measured using electroencephalography or implanted electrodes. Fight-or-flight response A physiological reaction to perceived threat or danger, involving the sympathetic nervous system and hormones such as epinephrine and cortisol. Forebrain The largest part of the brain, consisting of the cerebrum, thalamus, and hypothalamus. It is involved in complex behaviors, emotion, and cognition. Fornix A C-shaped bundle of white matter fibers that connects the hippocampus to the hypothalamus and other structures in the limbic system. Important for memory and emotional regulation.
Sources: en.wikipedia.org
== Interactions == Anastrozole is thought to have clinically negligible inhibitory effects on the cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2D6, CYP2C8, CYP2C9, and CYP2C19. As a result, it is thought that drug interactions of anastrozole with cytochrome P450 substrates are unlikely. No clinically significant drug interactions have been reported with anastrozole as of 2003. Anastrozole does not affect circulating levels of tamoxifen or its major metabolite N-desmethyltamoxifen. However, tamoxifen has been found to decrease steady-state area-under-the-curve levels of anastrozole by 27%. But estradiol levels were not significantly different in the group that received both anastrozole and tamoxifen compared to the anastrozole alone group, so the decrease in anastrozole levels is not thought to be clinically important.
== Regulation == The receptor tyrosine kinase (RTK) pathway is carefully regulated by a variety of positive and negative feedback loops. Because RTKs coordinate a wide variety of cellular functions such as cell proliferation and differentiation, they must be regulated to prevent severe abnormalities in cellular functioning such as cancer and fibrosis.
Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. For example, the JCR also includes a five-year impact factor, which is calculated by dividing the number of citations to the journal in a given year by the number of articles published in that journal in the previous five years.
==== Variability in pharmacokinetics ==== Transdermal estradiol patches are described as delivering a fixed amount of estradiol such as 50 μg/day or 100 μg/day. However, there is large interindividual variability and intraindividual variability in the pharmacokinetic parameters of transdermal estradiol, and fluctuations in circulating estradiol levels with estradiol patches are almost as great as with oral estradiol. As such, the actual delivery rate of estradiol and mean levels of estradiol achieved with transdermal estradiol patches may be different from what is described and from the mean levels observed in clinical studies, respectively. A wide range of estradiol levels are measured in women using the same estradiol patch or gel and dosage, with an up to about 10-fold difference in levels. In a study of estradiol gel and patches, the maximal difference in peak levels between individuals was 11-fold for the gel and 7-fold for the patch, and the maximal difference in area-under-the-curve levels (total exposure) was 6-fold for the gel and 8-fold for the patch. It has likewise been reported that the interindividual variability in bioavailability with Estraderm reservoir patches ranges from 25 to 225%. In as many as 30% of women treated with a 50 μg/day estradiol patch, estradiol levels are low. There are also significant short-term intraindividual differences in estradiol levels with estradiol patches; estradiol levels can fluctuate considerably from hour to hour.
In 2000, Shaw et al. demonstrated that circulating 3α-diol mediates prostate development in tammar wallaby pouch young via conversion to DHT in target tissues. Tammar wallaby pouch young do not show sexually dimorphic circulating levels of T and DHT during prostate development which suggests that another androgenization mechanism was responsible. While 3α-diol's androgen receptor binding affinity is five orders of magnitude lower than DHT (3α-diol is nearly inactive at the androgen receptor), it was known that 3α-diol can be oxidized back to DHT via the action of a number of dehydrogenases. In 2003, Wilson et al. demonstrated that 5α-reductase expression in target tissues enabled a novel pathway from 17OHP to 3α-diol without T or A4 as an intermediate. In 2004, Mahendroo et al. demonstrated that an overlapping novel pathway is operating in mouse testes, generalizing what had been demonstrated in tammar wallaby. The term "backdoor pathway" was coined by Auchus in 2004 and was described as 5α-reduction of 17α-hydroxyprogesterone (17OHP) which is a first step in a pathway that ultimately leads to the production of dihydrotestosterone (DHT). and defined as a route to DHT that: (1) bypasses conventional intermediates androstenedione (A4) and T; (2) involves 5α-reduction of C21 pregnanes to C19 androstanes; and (3) involves the 3α-oxidation of 3α-diol to DHT. The backdoor pathway explains how androgens are produced under certain normal and pathological conditions in humans when the classical androgen pathway cannot fully explain the observed consequences.
Sources: en.wikipedia.org
=== Operations === The LIMS is an evolving concept, with new features and functionality being added often. As laboratory demands change and technological progress continues, the functions of a LIMS will likely also change. Despite these changes, a LIMS tends to have a base set of functionality that defines it. That functionality can roughly be divided into five laboratory processing phases, with numerous software functions falling under each: (1) the reception and log in of a sample and its associated customer data, (2) the assignment, scheduling, and tracking of the sample and the associated analytical workload, (3) the processing and quality control associated with the sample and the utilized equipment and inventory, (4) the storage of data associated with the sample analysis, (5) the inspection, approval, and compilation of the sample data for reporting and/or further analysis. There are several pieces of core functionality associated with these laboratory processing phases that tend to appear in most LIMS:
The NHS questioned the benefits of the medication for depression and claimed that it was too expensive. People already using esketamine were allowed to complete treatment if their doctors considered this necessary. Esketamine is approved in the United States for and shows promise as a rapid-acting monotherapy for treatment-resistant depression, but evidence is currently limited to a single trial. It is an effective and generally safe long-term treatment for adults with treatment-resistant depression, feasible in outpatient settings; optimal oral antidepressant combinations and predictive biomarkers need further research. Spravato debuted at a cost of treatment of US$32,400 per year when it launched in the United States in March 2019. The Institute for Clinical and Economic Review (ICER), which evaluates cost effectiveness of drugs analogously to the National Institute for Health and Care Excellence (NICE) in the United Kingdom, declined to recommend esketamine for depression due to its steep cost and modest efficacy, deeming it not sufficiently cost-effective. Esketamine is the second drug to be approved for treatment-resistant depression by the FDA, following olanzapine/fluoxetine (Symbyax) in 2009. Other agents, like the atypical antipsychotics aripiprazole (Abilify) and quetiapine (Seroquel), have been approved for use in the adjunctive therapy of major depressive disorder in people with a partial response to treatment.
== Multicellular pharmacodynamics == The concept of pharmacodynamics has been expanded to include multicellular pharmacodynamics (MCPD). MCPD is the study of the static and dynamic properties and relationships between a set of drugs and a dynamic and diverse multicellular four-dimensional organization. It is the study of the workings of a drug on a minimal multicellular system (mMCS), both in vivo and in silico. Networked Multicellular Pharmacodynamics (Net-MCPD) further extends the concept of MCPD to model regulatory genomic networks together with signal transduction pathways, as part of a complex of interacting components in the cell.
Erythrocruorin Found in many annelids, including earthworms, it is a giant free-floating blood protein containing many dozens—possibly hundreds—of iron- and heme-bearing protein subunits bound together into a single protein complex with a molecular mass greater than 3.5 million daltons. Leghemoglobin In leguminous plants, such as alfalfa or soybeans, the nitrogen fixing bacteria in the roots are protected from oxygen by this iron heme containing oxygen-binding protein. The specific enzyme protected is nitrogenase, which is unable to reduce nitrogen gas in the presence of free oxygen. Coboglobin A synthetic cobalt-based porphyrin. Coboprotein would appear colorless when oxygenated, but yellow when in veins.
In September 2019, Taco Bell revamped its menu for the fall season. In July 2020, Taco Bell announced the Grilled Cheese Burrito. The burrito is a recurring menu item that occasionally reappears for a limited time.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
Lyophilised peptide powders are generally kept frozen or refrigerated, dry, and protected from light. Sealed vials limit moisture uptake and slow hydrolysis. Such guidance comes from general peptide chemistry rather than from stability studies specific to every product.